Hydrogen Therapy Shows Promise for Diabetic Kidney Disease Treatment
- Authors
- Shin-Ichi Hirano, Yusuke Ichikawa, Bunpei Sato, Yoshiyasu Takefuji, Fumitake Satoh
- Journal
- Biomedicines
- Year
- 2023
- DOI
- 10.3390/biomedicines11102817
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- Japan
- Health Condition
- Diabetic Kidney Disease
- Body System
- Renal
TL;DR
Scientists found that a simple gas called molecular hydrogen might help protect kidneys from damage caused by diabetes by reducing harmful chemicals in your cells and fighting inflammation. They're excited about it, but need to do bigger studies to prove it actually works in real patients.
Key Finding
Molecular hydrogen shows promise for diabetic kidney disease through its antioxidant and anti-inflammatory properties and ability to improve mitochondrial function, though large-scale human clinical trials are still needed to confirm effectiveness.
Summary
This review examined research on molecular hydrogen (H2), a gas with antioxidant properties, as a potential treatment for diabetic kidney disease (DKD)—a serious kidney complication of diabetes. The authors analyzed both animal studies and human trials and found that H2 may help by reducing harmful molecules called free radicals, decreasing inflammation, and improving how cells' energy-producing structures (mitochondria) function. However, the authors note that larger human studies are needed to confirm whether H2 actually works for kidney disease patients.
Practical Takeaway
While this review suggests H2 may have potential benefits for kidney disease based on preclinical and early clinical evidence, it is primarily a summary of existing research rather than a new study with definitive results. The authors explicitly call for larger human trials before H2 can be recommended clinically, so current evidence remains preliminary.
Abstract
As diabetes rates surge globally, there is a corresponding rise in the number of patients suffering from diabetic kidney disease (DKD), a common complication of diabetes. DKD is a significant contributor to chronic kidney disease, often leading to end-stage renal failure. However, the effectiveness of current medical treatments for DKD leaves much to be desired. Molecular hydrogen (H2) is an antioxidant that selectively reduces hydroxyl radicals, a reactive oxygen species with a very potent oxidative capacity. Recent studies have demonstrated that H2 not only possesses antioxidant properties but also exhibits anti-inflammatory effects, regulates cell lethality, and modulates signal transduction. Consequently, it is now being utilized in clinical applications. Many factors contribute to the onset and progression of DKD, with mitochondrial dysfunction, oxidative stress, and inflammation being strongly implicated. Recent preclinical and clinical trials reported that substances with antioxidant properties may slow the progression of DKD. Hence, we undertook a comprehensive review of the literature focusing on animal models and human clinical trials where H2 demonstrated effectiveness against a variety of renal diseases. The collective evidence from this literature review, along with our previous findings, suggests that H2 may have therapeutic benefits for patients with DKD by enhancing mitochondrial function. To substantiate these findings, future large-scale clinical studies are needed.